Your browser doesn't support javascript.
loading
Early Laser for Burn Scars (ELABS): protocol for a multi-centre randomised, controlled trial of both the effectiveness and cost-effectiveness of the treatment of hypertrophic burn scars with Pulsed Dye Laser and standard care compared to standard care alone [version 1; peer review: 2 approved].
Brewin, Mark; Docherty, Sharon; Heaslip, Vanessa; Breheny, Katie; Pleat, Jonathon; Rhodes, Shelley; van Zuijlen, Paul P M; Shah, Mamta.
Afiliação
  • Brewin M; Burns & Plastics, Salisbury NHS Foundation Trust, Salisbury, Wiltshire, SP2 8BJ, UK.
  • Docherty S; University of Bournemouth, Poole, Dorset, BH12 5BB, UK.
  • Heaslip V; University of Bournemouth, Poole, Dorset, BH12 5BB, UK.
  • Breheny K; University of Bristol, Bristol, BS8 1QU, UK.
  • Pleat J; Burns & Plastics, North Bristol NHS Trust, Bristol, BS10 5NB, UK.
  • Rhodes S; Exeter Clinical Trials Unit, University of Exeter, Exeter, EX4 4SB, UK.
  • van Zuijlen PPM; Red Cross Hospital, Beverwijk, The Netherlands Amsterdam UMC (location VUmc), Amsterdam, The Netherlands.
  • Shah M; Royal Manchester Children's Hospital, Manchester, UK.
NIHR Open Res ; 2: 1, 2022 Jan 18.
Article em En | MEDLINE | ID: mdl-35392303
ABSTRACT
This paper outlines the protocol for a study that is being carried out at multiple centres across the UK in the next three years. It is a Research for Patient Benefit (RfPB) study funded by the National Institute for Healthcare Research (NIHR). The aim is to assess the effectiveness of treating hypertrophic burns scars with pulsed dye laser (PDL) at an early stage of scar formation. The objective is to improve Quality of Life for the patient by improving both the appearance and quality of burn scarring, as well as reducing its psychological impact. This is a parallel-arm randomised, controlled trial to compare PDL and standard care against standard care alone. The difference is measured between baseline and six-month follow-up. Recruits are within three months of healing from a burn injury; with wounds showing a defined potential for hypertrophic scarring. A total of 120 patients are recruited in a multi-centre study; with randomisation in a 11 allocation to each arm. The treatment arm receives 3 PDL treatments at six-week intervals in addition to standard care, whereas the control arm receives standard care alone. The primary outcome is the patient-rated part of the Patient and Observer Scar Scale (POSAS). Psychological and psycho-social impact is evaluated using the CARe burn scale (UWE, Bristol) and Quality Adjusted Life Years (QALY) is determined using the Short-Form Health Survey (SF-12). The study evaluates both the cost-effectiveness through an economic analysis and the patient-reported experience of the treatment by phone interviews.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Guideline / Health_economic_evaluation Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Guideline / Health_economic_evaluation Idioma: En Ano de publicação: 2022 Tipo de documento: Article